Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

Company Overview

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Key Stats

• Today's Range: $4.26 to $4.26
• 50-Day Range: $4.15 to $4.29
• 52-Week Range: $2.06 to $4.50
• Volume: N/A
• Average Volume: 1.56 million shs
• Market Capitalization: $370.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Hold

Checkpoint Therapeutics Stock Analysis - MarketRank™

Checkpoint Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 895th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Hold

Consensus Rating

Checkpoint Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Checkpoint Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Checkpoint Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CKPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Checkpoint Therapeutics does not currently pay a dividend.

Dividend Growth

Checkpoint Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.63

Short Interest

There is no current short interest data available for CKPT.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Checkpoint Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.00% of the stock of Checkpoint Therapeutics is held by institutions.

CKPT Stock Analysis - Frequently Asked Questions

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.09.

When did Checkpoint Therapeutics' stock split?

Checkpoint Therapeutics's stock reverse split before market open on Sunday, December 4th 2022.The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' top institutional shareholders include Osaic Holdings Inc. (0.03%), Group One Trading LLC, Jane Street Group LLC and Equitec Proprietary Markets LLC. Insiders that own company stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include TG Therapeutics (TGTX), Bionano Genomics (BNGO), Fortress Biotech (FBIO), NIO (NIO), uniQure (QURE), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 9/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CKPT
• CIK: 1651407
• Web: www.checkpointtx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Checkpoint Therapeutics: $4.33
• High Price Target: $4.80
• Low Price Target: $4.10
• Potential Upside/Downside: +1.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.85 million
• Net Margins: N/A
• Pretax Margin: -98,868.08%
• Return on Equity: N/A
• Return on Assets: -659.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: $41 thousand
• Price / Sales: 9,041.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -9.06

Miscellaneous

• Outstanding Shares: 87,020,000
• Free Float: 47,808,000
• Market Cap: $370.71 million
• Optionable: Optionable
• Beta: 1.18